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Abstract
Background: Many antibiotics have no effect on Gram-positive and Gram-negative microbes, which necessitates
the prescription of broad-spectrum antimicrobial agents that can lead to increased risk of antibiotic resistance.
These pathogens constitute a further threat because they are also resistant to numerous beta-lactam antibiotics, as
well as other antibiotic groups. This study retrospectively investigates antimicrobial resistance in hospitalized
patients suffering from pneumonia triggered by Gram-negative Serratia marcescens or Proteus mirabilis.
Methods: The demographic and clinical data analyzed in this study were obtained from the clinical databank of
the HELIOS Clinic, Witten/Herdecke University, Wuppertal, Germany, for inpatients presenting with pneumonia
triggered by S. marcescens or P. mirabilis from 2004 to 2014. An antibiogram was conducted for the antibiotics
utilized as part of the management of patients with pneumonia triggered by these two pathogens.
Results: Pneumonia was caused by Gram-negative bacteria in 115 patients during the study period from January 1,
2004, to August 12, 2014. Of these, 43 (37.4 %) hospitalized patients [26 males (60.5 %, 95 % CI 45.9 %–75.1 %) and 17
females (39.5 %, 95 % CI 24.9 %–54.1 %)] with mean age of 66.2 ± 13.4 years had pneumonia triggered by S. marcescens,
while 20 (17.4 %) patients [14 males (70 %, 95 % CI 49.9 %–90.1 %) and 6 females (30 %, 95 % CI 9.9 %–50.1 %)] with a
mean age of 64.6 ± 12.8 years had pneumonia caused by P. mirabilis. S. marcescens showed an increased antibiotic
resistance to ampicillin (100 %), ampicillin-sulbactam (100 %), and cefuroxime (100 %). P. mirabilis had a high resistance
to tetracycline (100 %) and ampicillin (55 %). S. marcescens (P < 0.0001) and P. mirabilis (P = 0.0003) demonstrated no
resistance to cefepime in these patients with pneumonia.
Conclusions: S. marcescens and P. mirabilis were resistant to several commonly used antimicrobial agents, but showed
no resistance to cefepime.
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Background
Serratia marcescens and Proteus mirabilis are Gram-
negative bacteria that can cause pneumonia—an acute
infection of the lower airways caused by airborne infec-
tion or by infection transferred from another part of the
body via the bloodstream [1]. Gram-negative bacteria
are less often the cause of community- and nosocomial-
acquired pneumonia when compared to Gram-positive
bacteria [2–4].
S. marcescens is the most common species of the En-
terobacteriaceae family responsible for nosocomial infec-
tions [5, 6]. Proteus species are other Gram-negative
bacteria from the Enterobacteriaceae family [7], with P.
mirabilis being a medically prominent species [8]. Pro-
teus spp. cause most of the common urinary tract infec-
tions and are less frequently the causes of infections in
other locations, including pneumonia [8].
Penicillin has reliably helped to treat potentially fatal
bacterial infections for many decades [9]. However, anti-
biotics have lost their effectiveness due to the increasing
antibiotic resistance expressed by microbes [10]. Many
antibiotic resistant Gram-positive pathogens are recog-
nized, but antibiotic resistance is also becoming increas-
ingly common in Gram-negative bacteria [11]. Gram-
positive and Gram-negative microorganisms often can
only be fought with different antibiotics, making the
timely use of effective antibiotics particularly important
in patients with pneumonia.
Early identification of specific resistance characteristics
can result in a more effective use of antibiotics and can
limit the use of broad-spectrum antibiotics to serious in-
fections, thereby helping to prevent the development of
antibiotic resistance in S. marcescens and P. mirabilis.
Early isolation of infected patients can also help to stop
the spread of resistant bacteria.
For these reasons, this research was performed to
identify the antibiotics to which S. marcescens and P.
mirabilis have shown resistance over the past 10 years.
The records of the HELIOS Clinic at Witten/Herdecke
University in Wuppertal, Germany were searched to
gather all relevant files on hospitalized patients suffering
from pneumonia triggered by S. marcescens and P. mir-
abilis and classified according to the International Clas-
sification of Diseases (ICD) code J15.6 [12, 13]. The goal
of this investigation was to determine the most effective
selection of active antibiotics against S. marcescens and
P. mirabilis, in order to reduce the suffering of patients,




This retrospective observational study analyzed anti-
biotic resistance in all hospitalized patients over the age
of 18 years with identified pneumonia triggered by S.
marcescens or P. mirabilis. A parallel evaluation was
made of the antibiotic sensitivity and resistance of pa-
tients with pneumonia caused by S. marcescens and with
pneumonia due to P. mirabilis. All appropriate data were
acquired from files in the hospital databank of the HEL-
IOS Clinic at Witten/Herdecke University in Wuppertal,
Germany, for the duration of this investigation from
January 1, 2004, to August 12, 2014.
Definition of pneumonia
Pneumonia is an acute inflammation of the lower air-
ways that can be triggered by S. marcescens or P. mir-
abilis. The characteristic clinical signs of pneumonia are
productive cough, chest pain, fever, and shortness of
breath. Pneumonia is identified by chest X-ray investiga-
tion and expectorant cultures [12, 13].
Community-acquired pneumonia triggered by S. mar-
cescens or P. mirabilis is an acute respiratory tract infec-
tion picked up from ordinary communal interaction
with the public; this differs from nosocomial-acquired
pneumonia triggered by S. marcescens or P. mirabilis,
which occurs during hospitalization [14].
After a first empirical antibacterial treatment, the diag-
nosis of pneumonia caused by S. marcescens or P. mir-
abilis was based on the specific criteria that all patients
were hospitalized, all presented new areas of infiltration
on X-ray investigation, and all had novel clinical symp-
toms, including a minimum of two of the following
symptoms: difficulty breathing, fever over 38 °C, sputum
production, and coughing.
Investigated antibiotics
The effectiveness of the following antibiotics was exam-
ined against S. marcescens and P. mirabilis by susceptibil-
ity testing: ampicillin, piperacillin, ampicillin-sulbactam,
cefotaxime, cefuroxime, piperacillin-tazobactam, ceftazi-
dime, cefepime, meropenem, tobramycin, imipenem,
levofloxacin, ciprofloxacin, gentamicin, co-trimoxazole,
tetracycline, tigecycline, amikacin, and fosfomycin.
The incidence was noted of the application of the
above antimicrobial agents in clinical use for the therapy
of inpatients suffering from pneumonia triggered by S.
marcescens or P. mirabilis. The rate of susceptibility test-
ing of these antibiotics after discovery of S. marcescens
or P. mirabilis was also recorded. S. marcescens and P.
mirabilis causing pneumonia were assessed for suscepti-
bility to antibiotics and then the antimicrobial agent
showing the greatest resistance was checked against the
other antibiotics.
For Gram-negative pathogens, minimal inhibitory con-
centration (MIC) breakpoints were utilized that corre-
sponded to the antibiotic susceptibility testing guidelines
established by the Clinical and Laboratory Standards
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Institute (CLSI) for 2004 – 2011 [15], and by the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) for 2012 – 2014 [16].
Detection and antimicrobial susceptibility testing
Gram-negative bacteria were identified based on growth
on chocolate agar that included bacitracin (BD™ Mac-
Conkey Agar, Becton Dickinson, Heidelberg) after incu-
bation for 18–48 h at 37 °C with 5 % CO2. These
bacteria were identified as oxidase-positive, porphyrin-
negative bacteria needing nicotinamide adenine
dinucleotide plus heme in addition to missing beta-
hemolysis on horse blood agar plates, and by MALDI-
TOF-MS (Matrix Assisted Laser Desorption Ionization
Time-of-Flight-Mass Spectrometry, Bruker, Bremen,
Germany). Software suitable for the interpretation of
susceptibility testing results using the EUCAST break-
points for 2012 – 2014 was utilized for the antimicrobial
susceptibility testing [16]. Gram-negative isolates were
additionally examined using the API NH biochemical re-
action technique for the detection of Neisseria and Hae-
mophilus species (bioMérieux, Marcy-l’Étoile, France)
and by MALDI-TOF MS analysis (Daltonik, Bremen,
Germany).
EUCAST standardized disc diffusion method
The disc diffusion method established by Kirby-Bauer
was carried out for antimicrobial susceptibility testing
[17]. Mueller-Hinton culture medium was supplemented
with 5 % horse blood and 20 mg/L beta-nicotinamide
adenine dinucleotide (BD, Heidelberg, Germany). Plates
were inoculated with samples of each isolate and set to a
turbidity of 0.5 McFarland. Antibiotic discs were applied
to the dried surface of the inoculated culture medium
and later incubated at 35 ± 1 °C for 18 ± 2 h in a 5 %
CO2 atmosphere. In cases of discrepancies or insufficient
readings, the accurate determination of the MIC was ex-
ecuted by an E-test for particular pathogens, and the
outcomes were interpreted according to the EUCAST
criteria [16]. Intermediate isolates were grouped together
with resistant isolates. Beta-lactamase production was
evaluated using the nitrocefin test (Oxoid, Wesel,
Germany). Gram-negative strains were described as
beta-lactamase-negative strains that were resistant to
ampicillin (zone diameter > 16 mm or MIC ≥ 4 μg/mL)
[16]. Inhibition zone diameters were based on the 2014
EUCAST guidelines [16].
Microbiology
Bronchoalveolar lavage using fiber-optic video bronchos-
copy was performed for microbiological examination of
secretions from the pulmonary airways. After adminis-
tration of local anesthesia, approximately 20 ml of iso-
tonic saline was administered and aspirated by means of
the fiber-optic bronchoscope into three special sterilized
40-ml sample containers. In this way, tracheal secretions
were also obtained by means of bronchoscopy. Throat
smears were obtained by turning a sterile cotton swab
(MEUS Srl, Piove di Sacco, Italy) along the throats of in-
patients presumed to have pneumonia. Expectorate was
collected by ejection into 30-ml antiseptic sputum-
collection containers (Salivette, SARSTEDT, Nümbrecht,
Germany). The ejections, as well as the tracheal and
bronchial secretions, were Gram stained and examined
by light microscopy at 80–1,000-fold magnification in a
minimum of five viewing fields, following the principles
of Bartlett [18]. Three basic culture media were then
prepared for the growth of commonly occurring, rapidly
growing aerobic microbes.
Blood cultures
A least 20 ml of blood were added to two special cul-
ture media, BACTEC Plus Aerobic/F and Plus Anaer-
obic/F medium (BD, Becton, Dickinson and Company,
Heidelberg, Germany).
Duration of hospital stay
The lengths of hospital stays were compared between
patients with pneumonia caused by S. marcescens or P.
mirabilis.
Mortality
The number of fatalities during hospital stays was mea-
sured in the study population. The survival rates were
calculated by the Kaplan–Meier method.
Statistical analysis
The nominal variables were stated in percentages and
continuous data were indicated as mean ± standard devi-
ation (SD). Two-tailed tests were calculated. The results
were executed at a 95 % confidence interval (CI) for the
sex differentiation of inpatients suffering from pneumo-
nia triggered by S. marcescens or P. mirabilis. A chi-
square test for two free variables of three possibilities
was calculated on the VassarStats website for statistical
calculation to determine whether S. marcescens and P.
mirabilis were sensitive, intermediate, or resistant to
antimicrobial agents, and to calculate acquisitions of
pneumonia. A chi-square test was performed for two
free variables of two possibilities for gender differences
and deaths, and another chi-square test was performed
for two free variables of five possibilities for specimens
[19]. One-way analysis of variance (ANOVA) for two in-
dependent samples was performed to compare age dif-
ferences, duration of hospital stay, and laboratory tests
of patients with pneumonia caused by S. marcescens
or P. mirabilis. Statistical significance was defined as
a P value of less than 0.05.
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Ethics statement
The procedures of this retrospective study were per-
formed in agreement with the established official guide-
lines of Witten/Herdecke University. All patient data
were anonymized before evaluation. The Ethics Commit-
tee of Witten/Herdecke University approved this study
protocol. Due to the retrospective nature of the study
protocol, the committee waived the need for written in-
formed consent.
Results
A total of 6,932 patients of all ages were found with
pneumonia triggered by diverse kinds of microorganisms
at the HELIOS Clinic at Witten/Herdecke University in
Wuppertal, Germany at the time of this clinical study
from January 1, 2004, to August 12, 2014. Of these, 115
(1.7 %, 95 % CI 1.4 %–2.0 %) inpatients had pneumonia
triggered by Gram-negative bacteria (ICD J15.6). A total
of 43 (37.4 %, 95 % CI 28.6 %–46.2 %) inpatients were
identified for this investigation as having pneumonia
triggered by S. marcescens, and 20 (17.4 %, 95 % CI
10.5 %–24.3 %) inpatients had pneumonia due to P. mir-
abilis. Males were more frequently diagnosed with pneu-
monia triggered by S. marcescens or P. mirabilis
(Table 1). No gender difference was found when com-
paring patients with pneumonia caused by S. marcescens
or P. mirabilis (Table 1). S. marcescens and P. mirabilis
infections were responsible for the most nosocomial-
acquired pneumonia (Table 1). Gram-negative bacteria
were discovered in most tracheal secretions in both
groups of patients infected by these two organisms
(Table 1). The duration of hospital stays did not differ
between the two groups (Table 1).
An increase in cases of pneumonia was found over the
years of the study period (Fig. 1). The peak number of
cases of pneumonia due to S. marcescens occurred in
2010 and due to P. mirabilis in 2011 (Fig. 1).
Two kinds of Gram-negative bacteria were discovered
in the same patient in 9 cases with pneumonia. The
other Gram-negative bacteria, apart from S. marcescens
(43) and P. mirabilis (20), causing pneumonia during
this study period were Escherichia coli (10 cases), En-
terobacter cloacae (7), Stenotrophomonas maltophilia
(6), Acinetobacter baumannii (5), Enterobacter aerogenes
(3), Citrobacter koseri (1), Moraxella catarrhalis (1), Pre-
votella buccae (1), Proteus vulgaris (1), Citrobacter koseri
(1), and Serratia plymuthica (1).
Fifty-two inpatients were excluded from this investiga-
tion due to infectious diseases triggered by other Gram-
negative bacteria (37) or found in other locations in the
body (15), or because of a lack of access to their records
on the wards of the neurological department. In
addition, all children and adolescents under the age of
18 with pneumonia triggered by S. marcescens or P. mir-
abilis, and who were hospitalized on the wards of the
Division of Child and Adolescent Health, were excluded.
The number of examinations for each antimicrobial
agent differed in this investigation because a few isolates
Table 1 Demographic data, acquisition of pneumonia, length of hospital stay, mortality rate, and different discovery methods of
Serratia marcescens and Proteus mirabilis infection in patients with pneumonia
Total No. of Gram-negative bacteria pneumonia = 115 Serratia marcescens (%) Proteus mirabilis (%) P value
No. of patients 43 (37.4) 20 (17.4)
Gender
Male 26 (60.5) 14 (70) 0.655
Female 17 (39.5) 6 (30) 0.655
Age mean + SD (years) 66.2 ± 13.4 64.6 ± 12.8 0.648
Acquisition of pneumonia
Community-acquired pneumonia 15 (34.9) 6 (30) 0.083
Nosocomial-acquired pneumonia 23 (53.5) 7 (35) 0.083
Aspiration pneumonia 5 (11.6) 7 (35) 0.083
Specimens
Tracheal secretions 33 (76.7) 9 (45) 0.056
Bronchial secretions 7 (16.3) 5 (25) 0.056
Sputum 1 (2.3) 2 (10) 0.056
Throat swab 0 2 (10) 0.056
Venous blood culture 2 (4.7) 2 (10) 0.056
Duration of hospital stay mean ± SD (days) 22.2 ± 18.1 18.4 ± 13.4 0.392
No. of deaths 7 (16.3) 3 (15) 0.807
Abbreviations: SD standard deviation
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Fig. 1 Time trend of pneumonia due to Serratia marcescens and Proteus mirabilis from 2004 to 2014
Table 2 Antibiotic sensitivity and antibiotic resistance for different drug groups in patients with pneumonia caused by Serratia
marcescens
No. of patients with





No. of tests of
antibiotics on
antibiogram (%)
Sensitive (%) Intermediate (%) Resistant (%) P value
compared
to ampicillin
Penicillins Ampicillin 0 43 (100) 0 0 43 (100)






3 (7.0) 43 (100) 0 0 43 (100) 1.0
Piperacillin +
Tazobactam
21 (48.8) 43 (100) 38 (88.3) 1 (2.3) 4 (9.3) <0.0001
Cephalosporins Cefepime 2 (4.7) 39 (90.7) 39 (100) 0 0 <0.0001
Cefotaxime 0 43 (100) 36 (83.7) 2 (4.7) 5 (11.6) <0.0001
Ceftazidime 1 (2.3) 39 (90.7) 39 (100) 0 0 <0.0001
Cefuroxime 4 (9.3) 43 (100) 0 0 43 (100) 1.0
Glycylcycline Tetracycline 0 17 (39.5) 3 (17.6) 2 (11.8) 12 (70.6) 0.001
Tigecycline 0 5 (11.6) 3 (60.0) 2 (40.0) 0 <0.0001
Carbapenems Imipenem 5 (11.6) 43 (100) 42 (97.7) 0 1 (2.3) <0.0001
Meropenem 2 (4.7) 42 (97.7) 41 (97.6) 1 (2.4) 0 <0.0001
Gyrase inhibitors Ciprofloxacin 4 (9.3) 42 (97.7) 37 (88.1) 2 (4.8) 3 (7.1) <0.0001
Levofloxacin 3 (7.0) 28 (65.1) 26 (92.9) 0 2 (7.1) <0.0001
Aminoglycoside Amikacin 0 26 (60.5) 18 (69.2) 8 (30.8) 0 <0.0001
Gentamicin 2 (4.7) 40 (93.0) 38 (95.0) 2 (5.0) 0 <0.0001





0 42 (97.7) 39 (92.9) 0 3 (7.1) <0.0001
Others Fosfomycin 0 17 (39.5) 17 (100) 0 0 <0.0001
Note: Significant P values shown in bold
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were tested according to the CLSI guidelines, while
others were tested corresponding to the EUCAST guide-
lines over the past few years. In general, the sums of the
susceptibility tests were greater for the antibiograms ob-
tained according to the CLSI guidelines (Tables 2 and 3).
The most-used antibiotic in patients with pneumonia
due to S. marcescens or P. mirabilis in this research was
piperacillin-tazobactam (Tables 2 and 3).
Among the inpatients with pneumonia triggered by S.
marcescens or P. mirabilis, no resistance was found to
cefepime when compared to ampicillin; this finding was
statistically significant (Tables 2 and 3). S. marcescens
and P. mirabilis had the highest antibiotic-resistance
rates toward ampicillin, compared to cefepime, in this
research (Tables 2 and 3). S. marcescens also had an ele-
vated antibiotic-resistance rate toward ampicillin, as cor-
related with the ampicillin-sulbactam combination used
in this study (Table 2).
The mortality rate did not statistically differ be-
tween the study groups. The survival rate was 83.7 %
(95 % CI 71.7 %–95.8 %) in the study population with
pneumonia triggered by S. marcescens and 85.0 %
(95 % CI 68.0 %–102.0 %) in in the group infected
with P. mirabilis (Table 1).
Discussion
In general, S. marcescens and P. mirabilis are bacterial
strains that are not frequently found in pneumonia pa-
tients, as was also the case in the present study. No anti-
biotic resistance developed to cefepime—an antimicrobial
agent administered to patients with pneumonia—in either
S. marcescens or P. mirabilis during this ten-year, qualita-
tive, controlled observational investigation. An earlier clin-
ical study comparing the effectiveness of cefepime to six
other antibiotics commonly used in the management of
severe infections triggered by Gram-negative pathogens
indicated that the most effective antibiotics were cefepime
and imipenem [20]. A comparable result was found in an-
other investigation that evaluated cefepime as an initial
antibiotic treatment for Gram-negative pneumonia. A pre-
vious study had compared beta-lactam antibiotics against
Table 3 Antibiotic sensitivity and antibiotic resistance in different drug groups in patients with pneumonia caused by Proteus
mirabilis
No. of patients





No. of tests of
antibiotics on
antibiogram (%)
Sensitive (%) Intermediate (%) Resistant (%) P value
compared to
ampicillin
Penicillins Ampicillin 0 20 (100) 8 (40.0) 1 (5.0) 11 (55.0)





3 (15.0) 20 (100) 13 (65.0) 3 (15.0) 4 (20.0) 0.065
Piperacillin +
Tazobactam
15 (75.0) 20 (100) 20 (100) 0 0 0.0002
Cephalosporins Cefepime 0 19 (95.0) 19 (100) 0 0 0.0003
Cefotaxime 0 20 (100) 18 (90.0) 0 2 (10.0) 0.004
Ceftazidime 1 (5.0) 16 (80.0) 16 (100) 0 0 0.0007
Cefuroxime 0 20 (100) 15 (75.0) 0 5 (25.0) 0.068
Glycylcycline Tetracycline 0 13 (65.0) 0 0 13 (100) 0.018
Tigecycline 0 1 (5.0) 1 (100) 0 0 0.497
Carbapenems Imipenem 3 (15.0) 20 (100) 19 (95.0) 1(5.0) 0 0.0004
Meropenem 0 19 (95.0) 18 (94.7) 1 (5.3) 0 0.0006
Gyrase inhibitors Ciprofloxacin 1 (5.0) 18 (90.0) 15 (83.3) 1 (5.6) 2 (13.3) 0.016
Levofloxacin 1 (5.0) 14 (70.0) 13 (92.9) 1 (7.1) 0 0.003
Aminoglycoside Amikacin 0 9 (45.0) 9 (100) 0 0 0.01
Gentamicin 2 (10.0) 19 (95.0) 16 (84.2) 0 3 (15.8) 0.080





0 20 (100) 14 (70.0) 0 6 (30.0) 0.321
Others Fosfomycin 0 5 (25.0) 5 (100) 0 0 0.056
Note: Significant P values shown in bold
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all Gram-negative pathogens that cause pneumonia, and
based on that study’s outcome, cefepime was suggested as
an initial therapy for nosocomial-acquired pneumonia
triggered by Gram-negative pathogens [21].
Similar resistance rates were found for amikacin and
fosfomycin in the present work. Note, however, that the
sensitivities of these two antibiotics were significantly
lower than that of cefepime in this investigation. Amika-
cin has known effectiveness against Gram-negative
bacteria [22].
A previous retrospective study that investigated the
optimal first-antibiotic regimen for nosocomial-acquired
pneumonia triggered by Gram-negative bacteria detected
in sputum [23] indicated good effectiveness with imipe-
nem (75 %) and amikacin (84 %), based on antibiogram
results. In comparison, the sensitivity rate determined in
the present study was higher for imipenem (97.7 %) and
considerably lower for amikacin (69.2 %). The earlier
study took Pseudomonas into account in the evaluation
of the Gram-negative bacteria, but a direct comparison
of studies is often complicated because different conspe-
cifics were investigated under the collective term
“Gram-negative bacteria” [23].
The clinical efficacy of cefepime was previously con-
firmed by comparative and non-comparative studies
conducted many years ago [23, 24]. Cefepime was con-
sidered useful in the management of pneumonia, and it
is also active against organisms that show resistance to
other drugs [23, 24]. Fosfomycin is widely used for
nosocomial-acquired infections in hospitals because of
its good efficacy against Gram-negative bacteria [25, 26].
It can also be used in infections of the airways [27]. Mer-
openem is a broad-range antimicrobial agent effective
against Gram-positive and Gram-negative germs [28]
and has shown excellent efficacy in clinical studies for
the management of severe pneumonia in critical patients
[29]. Meropenem also showed good effectiveness and
relatively low resistance in all inpatients with pneumonia
due to S. marcescens and P. mirabilis over the course of
the present clinical research.
Good results were also found for levofloxacin in a pre-
vious study [29]. Levofloxacin was likewise found to be
effective in the present study for the management of pa-
tients with pneumonia triggered by S. marcescens or P.
mirabilis. The development of resistance to levofloxacin
was relatively low over the 10-year period covered by the
present investigation. It has good bacteriological effect-
iveness against a variety of infection diseases, and it is
also approved for the antibiotic management of
nosocomial-acquired infections [30].
When compared to levofloxacin, imipenem showed
better efficacy and a somewhat poorer resistance rate in
the present clinical study of hospitalized patients with
pneumonia triggered by S. marcescens or P. mirabilis.
Another study arrived at the same conclusion, where
levofloxacin was as effective as imipenem and was
tolerated well in patients with nosocomial-acquired
pneumonia [31].
A nationwide study conducted in Japan concluded that
ciprofloxacin had favorable susceptibility rates for treat-
ment of Gram-negative bacterial pneumonia [32], in
agreement with the findings of the present study. An-
other study that examined the effect of intravenous ad-
ministration of ciprofloxacin on nosocomial-acquired
pneumonia proposed intravenous ciprofloxacin as the
first choice for nosocomial-acquired pneumonia trig-
gered by both Gram-positive and Gram-negative
microbes [33].
Gentamicin is mostly effective against Gram-negative
microorganisms and shows activity against staphylococci
[34]. It had relatively good activity in the present study
in patients with pneumonia triggered by S. marcescens
or P. mirabilis. Both S. marcescens and P. mirabilis
showed resistance to gentamicin.
Ceftazidime is a valuable alternative for the manage-
ment of nosocomial-acquired pneumonia; nevertheless,
its role as an effective antimicrobial agent has decreased
over the past decade due to the strong increase in resist-
ance rates, especially for Pseudomonas aeruginosa and
Acinetobacter baumannii [35]. Pseudomonas was not the
focus of the investigation in the present research, but an
increasing development of antibiotic resistance of S.
marcescens and P. mirabilis against ceftazidime was
observed. Clinical studies have shown that the beta-lactam
inhibitor combination of piperacillin-tazobactam is an ef-
fective medication for patients suffering from nosocomial-
acquired pneumonia [36]. Piperacillin-tazobactam and
cefepime showed similar effectiveness against Gram-
negative bacteria, but S. marcescens and P. mirabilis devel-
oped greater resistance to piperacillin-tazobactam in the
present study. Due to this elevated resistance, piperacillin-
tazobactam represents an essential support option in the
treatment of nosocomial infections.
Resistance to tobramycin can be noted in numerous
stages and is generally high due to the preservation of
aminoglycoside-modifying enzymes [37]. Tobramycin
showed increasing resistance rates in S. marcescens and P.
mirabilis in the present study in hospitalized patients with
pneumonia. Tobramycin was not as commonly tested in
this study, but its efficacy was reduced in the antibiograms
of the hospitalized patients with pneumonia.
Co-trimoxazole (a combination of trimethoprim and
sulfamethoxazole) was effective in the study groups with
pneumonia due to S. marcescens or P. mirabilis, but
Gram-negative bacteria also showed significant resist-
ance to co-trimoxazole in the present study. The range
of effectiveness of the co-trimoxazole combination fa-
vors eradication of Gram-positive and Gram-negative
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microorganisms, although it is also effective against
protozoa and some types of fungi [38].
Cefotaxime acts against Gram-positive and Gram-
negative microbes, but elevated antibiotic resistance of S.
marcescens and P. mirabilis to cefotaxime was evident
in the present study population [39].
Tetracyclines are bacteriostatic toward Gram-positive
and Gram-negative microbes [40]. Despite the descrip-
tion of good efficacy of tetracycline in the medical litera-
ture, it was poorly effective against S. marcescens and P.
mirabilis pneumonia in the present investigation and in-
creased development of resistance was apparent in these
bacteria.
Piperacillin has the broadest range of activity of all
penicillins toward Gram-positive and Gram-negative mi-
croorganisms, including Pseudomonas and Enterobacte-
riaceae [41]. Piperacillin was significantly more effective
against Gram-negative isolates in patients with pneumo-
nia than were the other representatives of penicillin, but
S. marcescens and P. mirabilis showed resistance to it in
the present investigation. Piperacillin was more effective
against S. marcescens and P. mirabilis-associated pneu-
monia in the present study when combined with beta-
lactamase inhibitors.
Cefuroxime has increased activity against Gram-
negative rods when compared to first-generation
cephalosporins. It also shows high stability against beta-
lactamases [42]. Therefore, cefuroxime can be used for
the initial therapy of pneumonia due to beta-lactamase-
producing strains. In the current period of rapidly grow-
ing bacterial resistance, the appropriate use of new anti-
bacterial agents would be favored in the empirical
treatment of pneumonia [43]. Due to the resistance to
cefuroxime apparent in the antibiograms of isolates from
tracheal secretions of inpatients with pneumonia in the
present investigation, an empirical treatment would not
be recommended for suspected pneumonia due to S.
marcescens or P. mirabilis.
Ampicillin is effective against Gram-positive and some
Gram-negative microorganisms; therefore, it is called a
broad-range antimicrobial agent [44]. However, Gram-
negative bacteria in hospitalized patients suffering from
pneumonia showed the strongest resistance to ampicillin
in the present investigation. The susceptibility testing in-
dicated by the antibiograms of isolates recovered from
inpatients with pneumonia in this clinical research indi-
cated that S. marcescens and P. mirabilis were resistant to
ampicillin, as expected. Ampicillin in combination with
beta-lactam inhibitors showed better results, based on the
susceptibility testing of tracheal secretions from inpatients
with pneumonia triggered by S. marcescens or P. mirabilis
in this study. Ampicillin-sulbactam has proven to be an
important antimicrobial agent in the therapeutic arsenal
for the effective treatment of pneumonia [45].
Antibiotic resistance in pathogens causing respiratory
tract infections has increased dramatically in recent
years. Resistance to penicillins due to beta-lactamase
production has become a widespread problem around
the world [46]. The careful selection of antibiotics with
low potential for resistance, in addition to actively work-
ing against the further development of penicillin resist-
ance, is the best current strategy.
Study limitations
This clinical research explains the state of antibiotic re-
sistance in inpatients with pneumonia triggered by S.
marcescens or P. mirabilis in a single teaching hospital,
so the study results cannot be related to different geo-
graphical regions. Interpretation of the study data re-
vealed that not all of the antimicrobial agents were
examined in equal quantities in the susceptibility testing
of inpatients with pneumonia triggered by S. marcescens
or P. mirabilis. The authors were not able to clarify
whether all the antimicrobial agents were analyzed for
each isolate of S. marcescens and P. mirabilis.
Conclusions
All the study patients with pneumonia due to S. marces-
cens or P. mirabilis presented antibiotic resistance to a
diversity of antimicrobial agents, but none showed re-
sistance to cefepime. All common antimicrobial agents
must be examined for effectiveness in the event of detec-
tion of Gram-negative bacteria on agar plates, for all pa-
tients who are identified with pneumonia. This should
be done both for the immediate antimicrobial manage-
ment of patients with pneumonia triggered by Gram-
negative bacteria and for observing the temporal forma-
tion of antibiotic resistance in Gram-negative pathogens
in subsequent periods.
Abbreviations
CLSI: clinical and Laboratory Standards Institute; CRP: c-reactive protein;
CI: confidence interval; EUCAST: europe-wide standards for susceptibility
testing; ICD: international Classification of Diseases; MALDI-TOF-MS: matrix
assisted laser desorption ionization time-of-flight mass spectrometry;
MIC: minimum inhibitory concentration; SD: standard deviation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JY is responsible for the entire manuscript. The main author conceived and
designed the experiments, performed the experiments, and analyzed the
data. The main author contributed reagents, materials, and analysis tools.
The main author wrote the entire manuscript. BG was responsible for
microbiological testing and proofreading of the manuscript. KR was
responsible for the development of the study design and final approval of
the manuscript. All authors have read and approved of the final version of
the manuscript.
Author details
1Department of Internal Medicine, Division of Pulmonary, Allergy and Sleep
Medicine, HELIOS Clinic Wuppertal, Witten/Herdecke University, Witten,
Germany. 2Witten/Herdecke University, Institute of Medical Laboratory
Yayan et al. BMC Pharmacology and Toxicology  (2016) 17:10 Page 8 of 9
Diagnostics, Center for Clinical and Translational Research, HELIOS Clinic
Wuppertal, Witten, Germany.
Received: 19 September 2015 Accepted: 17 February 2016
References
1. Höffken G. Clinical requirements in the treatment of today’s respiratory tract
infections. Respiration. 1993;60 suppl 1:3–9.
2. Koulenti D, Rello J. Gram-negative bacterial pneumonia: aetiology and
management. Curr Opin Pulm Med. 2006;12:198–204.
3. Restrepo MI, Anzueto A. The role of gram-negative bacteria in healthcare-
associated pneumonia. Semin Respir Crit Care Med. 2009;30:61–6.
4. GlobalRPh. Gram Negative Bacteria, Gram-Negative Cocci & Coccobacilli,
Non-fermenting Gram-negative bacilli, Anaerobic Gram-Negative Bacilli.
2013. http://www.globalrph.com/bacterial-strains-gram-negative.htm.
Accessed 2 March 2015.
5. Wong WW, Wang LS, Cheng DL, Lin SJ, Chin TD, Hinthorn DR, et al. Serratia
marcescens bacteremia. J Formos Med Assoc. 1991;90:88–93.
6. Samonis G, Vouloumanou EK, Christofaki M, Dimopoulou D, Maraki S,
Triantafyllou E, et al. Serratia infections in a general hospital: characteristics
and outcomes. Eur J Clin Microbiol Infect Dis. 2011;30:653–60.
7. O’Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical
significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev.
2000;13:534–46.
8. Okimoto N, Hayashi T, Ishiga M, Nanba F, Kishimoto M, Yagi S, et al. Clinical
features of Proteus mirabilis pneumonia. J Infect Chemother. 2010;16:364–6.
9. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and
antibiotic management of community-acquired pneumonia in adults in
Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33:1065–79.
10. Woodhead M. Community-acquired pneumonia in Europe: causative
pathogens and resistance patterns. Eur Respir J Suppl. 2002;36:20s–7.
11. Zumla A, Memish ZA, Maeurer M, Bates M, Mwaba P, Al-Tawfig JA, et al.
Emerging novel and antimicrobial-resistant respiratory tract infections: new
drug development and therapeutic options. Lancet Infect Dis.
2014;14:1136–49.
12. World Health Organization (WHO). International classification of diseases
(ICD). http://www.who.int/classification/icd/en/. Accessed 2 March 2015.
13. Niederman MS, Mandell LA, Anzeuto A, Bass JB, Groughton WA, Campbell
GD, et al. American Thoracic Society. Guidelines for the management of
adults with community-acquired pneumonia. Diagnosis, assessment of
severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med.
2001;163:1730–54.
14. Watkins RR, Lemonovich TL. Diagnosis and management of community-
acquired pneumonia in adults. Am Fam Physician. 2011;83:1299–306.
15. Clinical and Laboratory Standards Institute. Performance standards for
antimicrobial susceptibility testing. CLSI M100-S22. Clinical and Laboratory
Standards Institute, Wayne, Pad; 2012.
16. European committee on antimicrobial susceptibility testing (EUCAST)
breakpoints 2011–2014. http://www.eucast.org. Accessed 2 March 2015.
17. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by
a standardized single disk method. Am J Clin Pathol. 1966;45:493–6.
18. Barlett JG. Diagnosis of bacterial infections of the lung. Clin Chest Med.
1987;8:119–34.
19. VassarStats [website for statistical computation] and Concepts &
Applications of Inferential Statistics [companion textbook]. http://vassarstats.
net/ and http://vassarstats.net/textbook/. Accessed 2 March 2015.
20. Tumah H. Fourth-generation cephalosporins: in vitro activity against
nosocomial gram-negative bacilli compared with beta-lactam antibiotics
and ciprofloxacin. Chemotherapy. 2005;51:80–5.
21. Burgess DS, Frei CR. Comparison of beta-lactam regimens for the treatment
of gram-negative pulmonary infections in the intensive care unit based on
pharmacokinetics/pharmacodynamics. J Antimicrob Chemother.
2005;56:893–8.
22. Montgomery AB, Rhomberg PR, Abuan T, Walters KA, Flamm RK.
Potentiation effects of amikacin and fosfomycin against selected amikacin-
nonsusceptible Gram-negative respiratory tract pathogens. Antimicrob
Agents Chemother. 2014;58:3714–9.
23. Green DL. Selection of an empiric antibiotic regimen for hospital-acquired
pneumonia using a unit and culture-type specific antibiogram. J Intensive
Care Med. 2005;20:296–301.
24. Chapman TM, Perry CM. Cefepime: a review of its use in the management
of hospitalized patients with pneumonia. Am J Respir Med. 2003;2:75–107.
25. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J
Infect Dis. 2011;15:e732–9.
26. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation
of the published evidence on the emergence of antimicrobial resistance in
Gram-negative pathogens. J Antimicrob Chemother. 2012;67:255–68.
27. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use
beyond urinary tract and gastrointestinal infections. Clin Infect Dis.
2008;46:1069–77.
28. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems:
past, present, and future. Antimicrob Agents Chemother. 2011;55:4943–60.
29. Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its
use in the treatment of serious bacterial infections. Drugs. 2008;68:803–38.
30. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of
bacterial infections in the United States. Drugs. 2003;63:2769–802.
31. West M, Boulanger BR, Fogarty C, Tennenberg A, Wiesinger B, Oross M, et al.
Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin
in adult patients with nosocomial pneumonia: a multicenter, prospective,
randomized, open-label study. Clin Ther. 2003;25:485–506.
32. Yamaguchi K, Ishii Y, Yamanaka K, Watanabe N, Uehara N, Kaku M, et al.
[Nationwide susceptibility surveillance of ciprofloxacin and various
parenteral antimicrobials against bacteria isolated from patients with severe
infections—third ciproxan injection special survey (2005)]. Jpn J Antibiot.
2008;61:241–68 [Article in Japanese].
33. Okimoto N, Yamato K, Honda Y, Kurihara T, Osaki K, Asaoka N, et al. Clinical
effect of intravenous ciprofloxacin on hospital-acquired pneumonia. J Infect
Chemother. 2005;11:52–4.
34. Chen C, Chen Y, Wu P, Chen B. Update on new medicinal applications of
gentamicin: evidence-based review. J Formos Med Assoc. 2014;113:72–82.
35. Choi SH, Koh Y. Ceftazidime for respiratory infections. Expert Opin
Pharmacother. 2012;13:2097–109.
36. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-
tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev
Anti Infect Ther. 2007;5:365–83.
37. Periti P. [Tobramycin—clinical pharmacology and chemotherapy].
J Chemother. 1996;8 suppl 1:3–30 [Article in Italian].
38. Cockerill FR, Edson RS. Trimethoprim-sulfamethoxazole. Mayo Clin Proc.
1991;66:1260–9.
39. Plosker GL, Foster RH, Benfield P. Cefotaxime. A pharmacoeconomic review
of its use in the treatment of infections. Pharmacoeconomics.
1998;13:91–106.
40. Griffin MO, Fricovsky E, Ceballos G, Villareal F. Tetracyclines: a pleitropic
family of compounds with promising therapeutic properties. Review of the
literature. Am J Physiol Cell Physiol. 2010;299:C539–48.
41. Holmes B, Richards DM, Brogden RN, Heel RC. Piperacillin. A review of its
antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs.
1984;28:375–425.
42. Ergova R, K‘oleian E, Kharalambieva I, Mitov I, Docheva LU. [A comparative
study of antibacterial activity of ceftibuten, ceftazidime, cefuroxime and
ampicillin against clinical isolates]. Vutr Boles. 2000;32:13–7 [Article in
Bulgarian].
43. Scott LJ, Ormrod D, Goa KL. Cefuroxime axetil: an updated review of its use
in the management of bacterial infections. Drugs. 2001;61:1455–500.
44. Kaushik D, Mohan M, Borade DM, Swami OC. Ampicillin: rise fall and
resurgence. Clin Diagn Res. 2014;8:ME01–3.
45. Wright AJ. The penicillins. Mayo Clin Proc. 1999;74:290–307.
46. Dominguez MA, Pallares R. Antibiotic resistance in respiratory pathogens.
Curr Opin Pulm Med. 1998;4:173–9.
Yayan et al. BMC Pharmacology and Toxicology  (2016) 17:10 Page 9 of 9
